Literature DB >> 29626448

Zoledronic Acid Induces Site-Specific Structural Changes and Decreases Vascular Area in the Alveolar Bone.

Mariana Quirino Silveira Soares1, Jeroen Van Dessel2, Reinhilde Jacobs3, Paulo Sérgio da Silva Santos4, Tania Mary Cestari5, Gustavo Pompermaier Garlet6, Marco Antonio Hungaro Duarte7, Thaís Sumie Nozu Imada8, Ivo Lambrichts9, Izabel Regina Fischer Rubira-Bullen4.   

Abstract

PURPOSE: The aim was to assess the effect of a relevant regimen of zoledronic acid (ZA) treatment for the study of bisphosphonate-related osteonecrosis of the jaw on alveolar bone microstructure and vasculature. A sub-objective was to use 3-dimensional imaging to describe site-specific changes induced by ZA in the alveolar bone.
MATERIALS AND METHODS: Five Wistar rats received ZA (0.6 mg/kg) and five (controls) received saline solution in the same volume. The compounds were administered intraperitoneally in 5 doses every 28 days. The rats were euthanized 150 days after therapy onset. The mandibles were scanned using high-resolution (14-μm) micro-computed tomography (micro-CT), decalcified, cut into slices for histologic analysis (5 μm), and stained with hematoxylin-eosin. Bone quality parameters were calculated using CT-Analyser software (Bruker, Kontich, Belgium) in 2 different volumes of interest (VOIs): the region between the first molar roots (VOI-1) and the periapical region under the first and second molars' apex (VOI-2). Blood vessel density and bone histomorphometric parameters were calculated only for the region between the roots of the first molar using AxioVision Imaging software (version 4.8; Carl Zeiss, Gottingen, Germany).
RESULTS: ZA-treated rats showed a significant increase in percentage of bone volume and density (P < .05), with thicker and more connected trabeculae. Furthermore, the ZA group showed a significant decrease in the size of the marrow spaces and nutritive canals and in blood vessel density (P < .05). In the micro-CT evaluation, VOI-2 showed better outcomes in measuring the effect of ZA on alveolar bone.
CONCLUSIONS: ZA treatment induced bone corticalization and decreased alveolar bone vascularization. VOI-2 should be preferred for micro-CT evaluation of the effect of bisphosphonates on alveolar bone. This analysis allowed the effect of ZA on alveolar bone and its vascularization to be characterized. The results of this analysis may add further knowledge to the understanding of the physiopathology of osteonecrosis of the jaw.
Copyright © 2018 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29626448     DOI: 10.1016/j.joms.2018.03.007

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  10 in total

1.  Micro-CT-Based Bone Microarchitecture Analysis of the Murine Skull.

Authors:  Jenny Tan; Agatha Labrinidis; Ruth Williams; Mustafa Mian; Peter J Anderson; Sarbin Ranjitkar
Journal:  Methods Mol Biol       Date:  2022

2.  Volumetric analysis of the periodontal microstructure under antiresorptive therapy: an experimental study in rabbits.

Authors:  Kathrin Becker; Robert Kerberger; Giulia Brunello; Joel Rockhoff; Nicole Rauch; Frank Schwarz
Journal:  Clin Oral Investig       Date:  2022-04-22       Impact factor: 3.606

3.  In vivo quantification of mandibular bone remodeling and vascular changes in a Wistar rat model: A novel HR-MRI and micro-CT fusion technique.

Authors:  Dandan Song; Sohaib Shujaat; Ruiting Zhao; Yan Huang; Eman Shaheen; Jeroen Van Dessel; Kaan Orhan; Greetje Vande Velde; Ruxandra Coropciuc; Ruben Pauwels; Constantinus Politis; Reinhilde Jacobs
Journal:  Imaging Sci Dent       Date:  2020-09-16

4.  Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients.

Authors:  Nils Heim; Werner Götz; Franz-Josef Kramer; Anton Faron
Journal:  Dentomaxillofac Radiol       Date:  2019-09-17       Impact factor: 2.419

Review 5.  Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Authors:  J I Aguirre; E J Castillo; D B Kimmel
Journal:  Bone       Date:  2021-09-11       Impact factor: 4.398

6.  Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats.

Authors:  Yu-Ting Cheng; Jian Liao; Qian Zhou; Hua Huo; Lucas Zellmer; Zheng-Long Tang; Hong Ma; Wei Hong; Dezhong Joshua Liao
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-29

7.  Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren's syndrome: nationwide population-based cohort study.

Authors:  Min-Tser Liao; Wu-Chien Chien; Jen-Chun Wang; Chi-Hsiang Chung; Shi-Jye Chu; Shih-Hung Tsai
Journal:  BMJ Open       Date:  2019-02-13       Impact factor: 2.692

Review 8.  From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights.

Authors:  Alexandre Anesi; Luigi Generali; Laura Sandoni; Samantha Pozzi; Alexis Grande
Journal:  Int J Mol Sci       Date:  2019-10-04       Impact factor: 5.923

9.  Effect of platelet-rich and platelet-poor plasma on 3D bone-to-implant contact: a preclinical micro-CT study.

Authors:  Dandan Song; Sohaib Shujaat; Yan Huang; Jeroen Van Dessel; Constantinus Politis; Ivo Lambrichts; Reinhilde Jacobs
Journal:  Int J Implant Dent       Date:  2021-02-18

10.  Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw.

Authors:  Henrique Hadad; Laís Kawamata de Jesus; Ana Flávia Piquera Santos; Henrique Rinaldi Matheus; Letícia Gabriella de Souza Rodrigues; Pier Paolo Poli; Elcio Marcantonio Junior; Fernando Pozzi Semeghini Guastaldi; Carlo Maiorana; Juliano Milanezi de Almeida; Roberta Okamoto; Francisley Ávila Souza
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.